Endoglin and activin receptor-like kinase 1 heterozygous mice have a distinct pulmonary and hepatic angiogenic profile and response to anti-VEGF treatment

Angiogenesis

Volumn 17, Issue 1, 2014, Pages 129-146

  Ardelean, Daniela S ^a,b   Jerkic, Mirjana ^a,b   Yin, Melissa ^c   Peter, Madonna ^a,b   Ngan, Bo ^a,d   Kerbel, Robert S ^c,d   Foster, F Stuart ^c,d   Letarte, Michelle ^a,b,d  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Angiogenesis; Anti angiogenic therapy; HHT; TGF ; TSP 1; VEGF

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; ANGIOPOIETIN 2; ENDOGLIN; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ACTIVIN RECEPTOR LIKE KINASE 1 GENE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; ENDOGLIN GENE; FEMALE; GENE EXPRESSION; HEPATOGRAPHY; HETEROZYGOTE; LIVER BLOOD VESSEL; LUNG BLOOD VESSEL; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ULTRASOUND; WILD TYPE;

ACTIVIN RECEPTORS, TYPE I; ANIMALS; ANTIBODIES, MONOCLONAL; HETEROZYGOTE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER; LUNG; MICE; MICE, MUTANT STRAINS; NEOVASCULARIZATION, PATHOLOGIC; RIBONUCLEASE, PANCREATIC; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84892711376     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-013-9383-4     Document Type: Article

References (66)

1. Shovlin CL (2010) Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 24(6):203-219. doi: 10.1016/j.blre.2010.07.001
2. Dupuis-Girod S, Bailly S, Plauchu H (2010) Hereditary hemorrhagic telangiectasia: from molecular biology to patient care. J Thromb Haemost 8(7):1447-1456. doi: 10.1111/j.1538-7836.2010.03860.x
3. Abdalla SA, Letarte M (2006) Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet 43(2):97-110. doi: 10.1136/jmg.2005.030833
4. Girerd B, Montani D, Coulet F, Sztrymf B, Yaici A, Jais X, Tregouet D, Reis A, Drouin-Garraud V, Fraisse A, Sitbon O, O'Callaghan DS, Simonneau G, Soubrier F, Humbert M (2010) Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med 181(8):851-861. doi: 10.1164/rccm.200908-1284OC
5. Mache CJ, Gamillscheg A, Popper HH, Haworth SG (2008) Early-life pulmonary arterial hypertension with subsequent development of diffuse pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia type 1. Thorax 63(1):85-86. doi: 10.1136/thx.2007.076109
6. Blanco FJ, Santibanez JF, Guerrero-Esteo M, Langa C, Vary CP, Bernabeu C (2005) Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. J Cell Physiol 204(2):574-584. doi: 10.1002/jcp.20311
7. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S (2007) Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 109(5):1953-1961. doi: 10.1182/blood-2006-07-034124
8. Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C, Karlsson S, ten Dijke P (2003) Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol Cell 12(4):817-828
9. Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G, Thorikay M, Mummery C, Arthur HM, ten Dijke P (2004) Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 23(20):4018-4028. doi: 10.1038/sj.emboj.7600386
10. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, Li L, Miyazono K, ten Dijke P, Kim S, Li E (2000) Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci USA 97(6):2626-2631. doi: 10.1073/pnas.97.6.2626
11. Lamouille S, Mallet C, Feige JJ, Bailly S (2002) Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis. Blood 100(13):4495-4501. doi: 10.1182/blood.V100.13.4495
12. Pardali E, Goumans MJ, ten Dijke P (2010) Signaling by members of the TGF-beta family in vascular morphogenesis and disease. Trends Cell Biol 20(9):556-567. doi: 10.1016/j.tcb.2010.06.006
13. Bourdeau A, Dumont DJ, Letarte M (1999) A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 104(10):1343-1351. doi: 10.1172/JCI8088
14. Urness LD, Sorensen LK, Li DY (2000) Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet 26(3):328-331. doi: 10.1038/81634
15. Bourdeau A, Faughnan ME, Letarte M (2000) Endoglin-deficient mice, a unique model to study hereditary hemorrhagic telangiectasia. Trends Cardiovasc Med 10(7):279-285. doi: 10.1016/S1050-1738(01)00062-7
16. Srinivasan S, Hanes MA, Dickens T, Porteous ME, Oh SP, Hale LP, Marchuk DA (2003) A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2. Hum Mol Genet 12(5):473-482
17. Bourdeau A, Faughnan ME, McDonald ML, Paterson AD, Wanless IR, Letarte M (2001) Potential role of modifier genes influencing transforming growth factor-beta1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia. Am J Pathol 158(6):2011-2020. doi: 10.1016/S0002-9440(10)64673-1
18. Park SO, Wankhede M, Lee YJ, Choi EJ, Fliess N, Choe SW, Oh SH, Walter G, Raizada MK, Sorg BS, Oh SP (2009) Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. J Clin Invest 119(11):3487-3496. doi: 10.1172/JCI39482
19. Mahmoud M, Allinson KR, Zhai Z, Oakenfull R, Ghandi P, Adams RH, Fruttiger M, Arthur HM (2010) Pathogenesis of arteriovenous malformations in the absence of endoglin. Circ Res 106(8):1425-1433. doi: 10.1161/CIRCRESAHA.109. 211037
20. Jerkic M, Sotov V, Letarte M (2012) Oxidative stress contributes to endothelial dysfunction in mouse models of hereditary hemorrhagic telangiectasia. Oxid Med Cell Longev 2012:686972. doi: 10.1155/2012/686972
21. Toporsian M, Jerkic M, Zhou YQ, Kabir MG, Yu LX, McIntyre BA, Davis A, Wang YJ, Stewart DJ, Belik J, Husain M, Henkelman M, Letarte M (2010) Spontaneous adult-onset pulmonary arterial hypertension attributable to increased endothelial oxidative stress in a murine model of hereditary hemorrhagic telangiectasia. Arterioscler Thromb Vasc Biol 30(3):509-517. doi: 10.1161/ATVBAHA.109.200121
22. Jerkic M, Kabir MG, Davies A, Yu LX, McIntyre BA, Husain NW, Enomoto M, Sotov V, Husain M, Henkelman M, Belik J, Letarte M (2011) Pulmonary hypertension in adult Alk1 heterozygous mice due to oxidative stress. Cardiovasc Res 92(3):375-384. doi: 10.1093/cvr/cvr232
23. Torsney E, Charlton R, Diamond AG, Burn J, Soames JV, Arthur HM (2003) Mouse model for hereditary hemorrhagic telangiectasia has a generalized vascular abnormality. Circulation 107(12):1653-1657. doi: 10.1161/01.CIR.0000058170. 92267.00
24. Hlatky L, Hahnfeldt P, Folkman J (2002) Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94(12):883-893
25. Bourdeau A, Cymerman U, Paquet ME, Meschino W, McKinnon WC, Guttmacher AE, Becker L, Letarte M (2000) Endoglin expression is reduced in normal vessels but still detectable in arteriovenous malformations of patients with hereditary hemorrhagic telangiectasia type 1. Am J Pathol 156(3):911-923. doi: 10.1016/S0002-9440(10)64960-7
26. Rinaldi M, Buscarini E, Danesino C, Chiosi F, De Benedictis A, Porcellini A, Costagliola C (2011) Ocular manifestations in hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber disease): a case-series. Ophthalmic Genet 32(1):12-17. doi: 10.3109/13816810.2010.535891
27. Sadick H, Riedel F, Naim R, Goessler U, Hormann K, Hafner M, Lux A (2005) Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 90(6):818-828
28. Sadick H, Naim R, Gossler U, Hormann K, Riedel F (2005) Angiogenesis in hereditary hemorrhagic telangiectasia: VEGF165 plasma concentration in correlation to the VEGF expression and microvessel density. Int J Mol Med 15(1):15-19
29. Hao Q, Zhu Y, Su H, Shen F, Yang GY, Kim H, Young WL (2010) VEGF induces more severe cerebrovascular dysplasia in endoglin than in Alk1 mice. Transl Stroke Res 1(3):197-201. doi: 10.1007/s12975-010-0020-x
30. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358(19):2039-2049. doi: 10.1056/NEJMra0706596
31. Mitchell A, Adams LA, MacQuillan G, Tibballs J, van den Driesen R, Delriviere L (2008) Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl 14(2):210-213. doi: 10.1002/lt.21417
32. Bose P, Holter JL, Selby GB (2009) Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 360(20):2143-2144. doi: 10.1056/NEJMc0901421
33. Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Lorcerie B, Riviere S, Corre R, Giraud S, Bailly S, Paintaud G, Ternant D, Valette PJ, Plauchu H, Faure F (2012) Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 307(9):948-955. doi: 10.1001/jama.2012.250
34. Pettersson A, Nagy JA, Brown LF, Sundberg C, Morgan E, Jungles S, Carter R, Krieger JE, Manseau EJ, Harvey VS, Eckelhoefer IA, Feng D, Dvorak AM, Mulligan RC, Dvorak HF (2000) Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest 80(1):99-115
35. Seki T, Yun J, Oh SP (2003) Arterial endothelium-specific activin receptor-like kinase 1 expression suggests its role in arterialization and vascular remodeling. Circ Res 93(7):682-689. doi: 10.1161/01.RES.0000095246. 40391.3B
36. Liang WC, Wu X, Peale FV, Lee CV, Meng YG, Gutierrez J, Fu L, Malik AK, Gerber HP, Ferrara N, Fuh G (2006) Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 281(2):951-961. doi: 10.1074/jbc.M508199200
37. Foster FS, Hossack J, Adamson SL (2011) Micro-ultrasound for preclinical imaging. Interface Focus 1(4):576-601. doi: 10.1098/rsfs.2011.0037
38. Guignabert C, Alvira CM, Alastalo TP, Sawada H, Hansmann G, Zhao M, Wang L, El-Bizri N, Rabinovitch M (2009) Tie2-mediated loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF receptor-beta- dependent pulmonary arterial muscularization. Am J Physiol Lung Cell Mol Physiol 297(6):L1082-L1090. doi: 10.1152/ajplung.00199.2009
39. Pece-Barbara N, Vera S, Kathirkamathamby K, Liebner S, Di Guglielmo GM, Dejana E, Wrana JL, Letarte M (2005) Endoglin null endothelial cells proliferate faster and are more responsive to transforming growth factor beta1 with higher affinity receptors and an activated Alk1 pathway. J Biol Chem 280(30):27800-27808. doi: 10.1074/jbc.M503471200
40. Loupakis F, Falcone A, Masi G, Fioravanti A, Kerbel RS, Del Tacca M, Bocci G (2007) Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. J Clin Oncol 25(13):1816-1818. doi: 10.1200/JCO.2006.10.3051
41. Baffert F, Thurston G, Rochon-Duck M, Le T, Brekken R, McDonald DM (2004) Age-related changes in vascular endothelial growth factor dependency and angiopoietin-1-induced plasticity of adult blood vessels. Circ Res 94(7):984-992. doi: 10.1161/01.RES.0000125295.43813.1F
42. Lawler PR, Lawler J (2012) Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med 2(5):a006627. doi: 10.1101/cshperspect.a006627
43. Park S, Dimaio TA, Liu W, Wang S, Sorenson CM, Sheibani N (2013) Endoglin regulates the activation and quiescence of endothelium by participating in canonical and non-canonical TGF-beta signaling pathways. J Cell Sci. doi: 10.1242/jcs.117275
44. Shao ES, Lin L, Yao Y, Bostrom KI (2009) Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells. Blood 114(10):2197-2206. doi: 10.1182/blood-2009-01-199166
45. Choi EJ, Walker EJ, Shen F, Oh SP, Arthur HM, Young WL, Su H (2012) Minimal homozygous endothelial deletion of eng with VEGF stimulation is sufficient to cause cerebrovascular dysplasia in the adult mouse. Cerebrovasc Dis 33(6):540-547. doi: 10.1159/000337762
46. Walker EJ, Su H, Shen F, Degos V, Jun K, Young WL (2012) Bevacizumab attenuates VEGF-induced angiogenesis and vascular malformations in the adult mouse brain. Stroke 43(7):1925-1930. doi: 10.1161/STROKEAHA.111.647982
47. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, Waltenberger J, Voelkel NF, Tuder RM (2001) Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 15(2):427-438. doi: 10.1096/fj.00-0343com
48. Rose A, Grandoch M, vom Dorp F, Rubben H, Rosenkranz A, Fischer JW, Weber AA (2010) Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells. Br J Pharmacol 160(7):1690-1698. doi: 10.1111/j.1476-5381. 2010.00838.x
49. Conery AR, Cao Y, Thompson EA, Townsend CM Jr, Ko TC, Luo K (2004) Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta induced apoptosis. Nat Cell Biol 6(4):366-372
50. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N (2000) Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 6(1):41-48. doi: 10.1038/71517
51. Ochoa CD, Yu L, Al-Ansari E, Hales CA, Quinn DA (2010) Thrombospondin-1 null mice are resistant to hypoxia-induced pulmonary hypertension. J Cardiothorac Surg 5:32. doi: 10.1186/1749-8090-5-32
52. Greenaway J, Lawler J, Moorehead R, Bornstein P, Lamarre J, Petrik J (2007) Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J Cell Physiol 210(3):807-818. doi: 10.1002/jcp.20904
53. Kaur S, Martin-Manso G, Pendrak ML, Garfield SH, Isenberg JS, Roberts DD (2010) Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J Biol Chem 285(50):38923-38932. doi: 10.1074/jbc.M110.172304
54. Guo N, Krutzsch HC, Inman JK, Roberts DD (1997) Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 57(9):1735-1742
55. Kumpers P, Nickel N, Lukasz A, Golpon H, Westerkamp V, Olsson KM, Jonigk D, Maegel L, Bockmeyer CL, David S, Hoeper MM (2010) Circulating angiopoietins in idiopathic pulmonary arterial hypertension. Eur Heart J 31(18):2291-2300. doi: 10.1093/eurheartj/ehq226
56. Fiedler U, Augustin HG (2006) Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 27(12):552-558. doi: 10.1016/j.it.2006.10.004
57. Lobov IB, Brooks PC, Lang RA (2002) Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 99(17):11205-11210. doi: 10.1073/pnas.172161899
58. Cao Y, Sonveaux P, Liu S, Zhao Y, Mi J, Clary BM, Li CY, Kontos CD, Dewhirst MW (2007) Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth. Cancer Res 67(8):3835-3844. doi: 10.1158/0008-5472.CAN-06-4056
59. Zhang L, Yang N, Park JW, Katsaros D, Fracchioli S, Cao G, O'Brien-Jenkins A, Randall TC, Rubin SC, Coukos G (2003) Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 63(12):3403-3412
60. DeLeve LD, Wang X, Hu L, McCuskey MK, McCuskey RS (2004) Rat liver sinusoidal endothelial cell phenotype is maintained by paracrine and autocrine regulation. Am J Physiol Gastrointest Liver Physiol 287(4):G757-G763. doi: 10.1152/ajpgi.00017.2004
61. Baffert F, Le T, Sennino B, Thurston G, Kuo CJ, Hu-Lowe D, McDonald DM (2006) Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol 290(2):H547-H559. doi: 10.1152/ajpheart.00616.2005
62. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM (2006) VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290(2):H560-H576. doi: 10.1152/ajpheart.00133.2005
63. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M (2009) Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 49(4):1245-1256. doi: 10.1002/hep.22758
64. Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodes J, Bosch J (2004) Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 126(3):886-894. doi: 10.1053/j.gastro.2003.12.012
65. Korsisaari N, Kasman IM, Forrest WF, Pal N, Bai W, Fuh G, Peale FV, Smits R, Ferrara N (2007) Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice. Proc Natl Acad Sci USA 104(25):10625-10630. doi: 10.1073/pnas.0704213104
66. Belcik JT, Qi Y, Kaufmann BA, Xie A, Bullens S, Morgan TK, Bagby SP, Kolumam G, Kowalski J, Oyer JA, Bunting S, Lindner JR (2012) Cardiovascular and systemic microvasculareffects of anti-vascular endothelial growth factor therapy for cancer. J Am Coll Cardiol 60(7):618-625. doi: 10.1016/j.jacc.2012.02.053